(Reuters) – Novo Nordisk’s blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways. Both treatments contain the active ingredient semaglutide, part of a class known as GLP-1 drugs that work by helping control blood sugar levels and triggering a feeling of fullness. New...